Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN21353 Alone or With Nezastomig in mCRPC
NCT07850921Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2027
- Primary completion
- Jul 2031
01
Overview
Phase 2 trial of REGN21353 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment Emergent Adverse Events up to 5 years, Occurrence of Dose-Limiting Toxicities up to 42 days and 3 more. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
REGN21353
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07850921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850921.